Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $402000.0.

  • Utah Medical Products' Asset Writedowns and Impairment changed N/A to $402000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $397000.0, marking a year-over-year increase of 506250.0%. This contributed to the annual value of -$4000.0 for FY2024, which is 8787.88% up from last year.
  • Latest data reveals that Utah Medical Products reported Asset Writedowns and Impairment of $402000.0 as of Q3 2025.
  • Utah Medical Products' 5-year Asset Writedowns and Impairment high stood at $402000.0 for Q3 2025, and its period low was -$27000.0 during Q2 2023.
  • Over the past 5 years, Utah Medical Products' median Asset Writedowns and Impairment value was $2000.0 (recorded in 2021), while the average stood at $22888.9.
  • As far as peak fluctuations go, Utah Medical Products' Asset Writedowns and Impairment soared by 50000.0% in 2021, and later plummeted by 90000.0% in 2024.
  • Quarter analysis of 5 years shows Utah Medical Products' Asset Writedowns and Impairment stood at $4000.0 in 2021, then skyrocketed by 125.0% to $9000.0 in 2022, then plummeted by 122.22% to -$2000.0 in 2023, then soared by 200.0% to $2000.0 in 2024, then skyrocketed by 20000.0% to $402000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $402000.0 for Q3 2025, versus $2000.0 for Q2 2025 and -$9000.0 for Q1 2025.